Navigation Links
Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
Date:1/3/2008

CRANBURY, N.J., Jan. 2 /PRNewswire-FirstCall/ -- Amicus Therapeutics Inc. (Nasdaq: FOLD), today announced that John F. Crowley, President and Chief Executive Officer, will present a corporate update at the 26th Annual JPMorgan Healthcare Conference in San Francisco, CA on Monday, January 7, 2008 at 11:30 am (Pacific Standard Time) at the Westin St. Francis Hotel.

The presentation will be webcast live and may be accessed by visiting Amicus' website at http://www.amicustherapeutics.com. A replay of the webcast will also be available on the Company's website until January 22, 2008.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. The Company has completed Phase 1 clinical trials of AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

Amicus cautions you that statements included in this press release that are not a description of historical facts are "forward-looking statements" within the meaning of Section 21E of the Private Securities Litigation Reform Act of
'/>"/>

SOURCE Amicus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., ,, ANDOVER,Mass.,Nov.24/PRNewswire/--Visag...icusLtd.(ASX:PME),willbeintroducingVisage®7,t...n,attheAnnualConferenceoftheRadiologicSocietyofNor...o,IL. ,, Visage®7deliversnewlevelsofversat...b-specialists,andreferringphysicians.TheVisage7Uni...
(Date:11/24/2009)..., SANDIEGO,Nov.24/PRNewswire-FirstCall/--OptimerPh...entatthe21stAnnualPiperJaffrayHealthCareConference...:00p.m.EasternTime. ,, (Logo: http://www.newsco...iveaudiowebcastofthispresentationwillbeaccessibleo...merpharma.com .Replaysofthispresentationwillbeava...
(Date:11/24/2009)..., SANMATEO,Calif.,Nov.24/PRNewswire-FirstCall/--Ne...anyfocusedondevelopingandcommercializingnovelpainm...ohnA.OrwintoitsBoardofDirectors,effectiveNovember1...nthebiopharmaceuticalindustryandhasbeeninstrumenta...Mr.OrwincurrentlyservesasSeniorVicePresident,BioOn...
Breaking Medicine Technology:Visage Imaging Introduces Visage(R) 7 for Windows and Mac OS X 2NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director 2NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director 3How to reach proficiency in laparoscopic splenectomy 3F 57347 1AAPS and PhRMA co sponsor stability workshop 9947 1AAPS and PhRMA co sponsor stability workshop 9947 2Sales Force Sizing and Resource Optimization Software Is the First of Its Kind to Enter the Market 28Beta Release 29 57341 1Sales Force Sizing and Resource Optimization Software Is the First of Its Kind to Enter the Market 28Beta Release 29 57341 2
...ax Will Remain the NSTEMI Market Share Leader Thro...Resources , , WALTHAM, Mass., Feb. 25 Decision R...advisory firms for pharmaceutical and healthcare i...of mortality at 30 days is the attribute that most...cisions in non-ST elevation myocardial infarction ...
...res and infections of the bone are among most seri...Severe musculoskeletal conditions in children incl... as slipped epiphysis, and elbow fractures. These ...mplications if children are not treated properly a...leased today at the 2009 Annual Meeting of the Am...
Other Medicine Technology:Angiomax Will Retain Decision Resources' Proprietary Clinical Gold Standard Status Over Current and New Therapies, Including Recently-Approved Efient, for the Treatment of NSTEMI 2Angiomax Will Retain Decision Resources' Proprietary Clinical Gold Standard Status Over Current and New Therapies, Including Recently-Approved Efient, for the Treatment of NSTEMI 3Children and Orthopaedic Surgical Emergencies 2Children and Orthopaedic Surgical Emergencies 3
(Date:11/25/2009)... Beginning Today through Sunday, Novembe...ery memory foam and latex sofa bed mattress + an a...ng and a 100 night money back guarantee. Use the c... to take advantage of this special offer. , ...llions of Americans will travel from Thanksgiving ...
(Date:11/25/2009)... The American Society of Hematology (ASH...ishing, education, and media company, are launchin...namic science curriculum designed to spark interes...on to exposing students to exciting career opportu...ashington (PRWEB) November 25, 2009 -- The America...
(Date:11/25/2009)...November25/PRNewswire/--Therearemanywaysyoucanimpr...sults.Butthere,alwaysseemstobeconflictingadvicecon...rhealth. , So,therealbuzz.comteamhascompileda...tymuchincontrovertible!Doingacombinationof,oursugg...festyle,andwell-being-sotrythemout. , 1.Reduc...
(Date:11/24/2009)... amounts of salt is linked to a significantly high...tes a paper published today in the British Medica...ly by the World Health Organization,s Collaboratin... Warwick and University Hospital in Coventry, UK, ...e Centre in Hypertension based at the Department o...
(Date:11/24/2009)...ELDHILLS,Mich.,Nov.24/PRNewswire/--SkyFoundation,I...0tofundresearchtodevelopabloodtestfortheearlydetec...rethat$100,000sinceitsinceptioninJune2008.Theannou...dation,aftertheorganization,sfirstmajorfundraiser....ovember8,atabrunchatTheVillageClubinBloomfieldHill...
Breaking Medicine News(10 mins):Health News:Providing Comfort for Holiday Guests Just Got Easier 2Health News:Providing Comfort for Holiday Guests Just Got Easier 3Health News:New Science Program Teaches High School Students About Blood and Career Opportunities in the Field of Hematology 2Health News:New Science Program Teaches High School Students About Blood and Career Opportunities in the Field of Hematology 3Health News:realbuzz.com - Top 25 Ways to Improve Your Health & get a Better Sex Life! 2Health News:High salt intake linked to strokes and cardiovascular disease 2Health News:Sky Foundation, Inc. Raises More Than $100,000 to Find a Test for Early Detection of Pancreatic Cancer 2
...published in the latest issue of BMJ said that mul...prevent infections in the elderly population. ...neral deficiency, which can lead to poor immunity ...fluence on infections. Researchers at Aberdee...
...he choice by many for latest and quick medical tre...year-old son, Elliot Knott to India for treatment ... an operation in the NHS. The decision to s...ft housebound from an ice-skating injury, then fac...
...ration FDA has recently announced that it has plan...rug advertisements. The FDA and the pharmaceu...ising practices for drugs, with agency research sh...tical industry advertising led to revised guidelin...
...m will Friday inaugurate the world's first state-o...ormatics here. Jointly established and managed...ics (CDFD) and Sun Microsystems Inc, the centre wi...ng a network of computers in a grid system. W...
... programmes that involve high doses of vitamins an... unwitting 'guinea pigs', according to British res...m effects there might be from taking supplements a...ssionals who turned to vitamins and minerals in se...
...issue of Harvard Women’s Health Watch had explored...me women in their menopausal or postmenopausal age...al women—and to many who are in peri-menopause, th...a feeling of being on fire. Although the phy...
Other Medicine News:Health News:Indian Hospitals – A Destination For Quality Medical Care 2Health News:New Bioinformatics Centre to open in Andhra 2Health News:Vitamin Supplements - Good, The Bad And The Ugly 2Health News:Vitamin Supplements - Good, The Bad And The Ugly 3Health News:Insight for Hot Flashes In Postmenopausal Women 2
Thorpe Corneal Fixation Forceps
Pierse Type Straight Micro Forceps
Pierse Type Micro Skeleton Forceps
Moody Curved Fixation Forceps
Medicine Products: